On Jan. 21, 2019, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) announced that it had closed the previously announced MOU with Dayacann, holder of Chile's first and only medical cannabis cultivation license.
Dayacann is a joint venture entity established by Fundacion Daya and its Australian partner AusCann Group Holdings Ltd.
Khiron, with core operations in Colombia, is positioned to be the dominant integrated medical cannabis company in Latin America. This agreement expands on Khiron's multi jurisdiction cultivation strategy, securing access to cannabis cultivation for the company's use in Chile, participation in clinical trials, and access to commercialize products to meet the needs of a market of 1.8 million patients across the country.
Gowling WLG advised Khiron with respect to this acquisition with a team that included Peter Simeon, Marek Lorenc and Josh Rosen.
Read the original article on GowlingWLG.com
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
